Ophirex Revenue and Competitors

Corte Madera, CA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ophirex's estimated annual revenue is currently $2.6M per year.(i)
  • Ophirex's estimated revenue per employee is $77,500

Employee Data

  • Ophirex has 34 Employees.(i)
  • Ophirex grew their employee count by 6% last year.

Ophirex's People

NameTitleEmail/Phone
1
CEO, FounderReveal Email/Phone
2
CEOReveal Email/Phone
3
CEOReveal Email/Phone
4
Chief Development OfficerReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
VP FinanceReveal Email/Phone
7
SVP for Translational ScienceReveal Email/Phone
8
SVP, Translational ScienceReveal Email/Phone
9
SVP, India Clinical Research & Medical AffairsReveal Email/Phone
10
SVP, Commercial, Global Access and CommunicationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Ophirex?

Ophirex, Inc., a Public Benefit Corp. focused on treatments for acute, life-threatening illnesses, is modernizing the treatment of snakebite victims by developing an affordable, accessible, oral treatment for immediate use anywhere a snake’s bite occurs. Approximately 80% of the world’s population lives in close proximity to at least one venomous snake species and more than 500,000 people are killed or maimed by snakes each year worldwide.[1][2] Field treatments could help save hundreds of thousands of lives and limbs annually and provide enormous savings in healthcare costs.[2][3] Ophirex is developing a “time of bite” oral snakebite treatment that blocks the most commonly lethal component of snake venom—present in 95% of the world’s venomous snakes.[4] This antidote—now in human clinical trials—can be administered immediately in the field or in the hospital to effectively stop the venom’s devastating assault.[5][6][7] 1. Vulnerability to snakebite envenoming: a global mapping of hotspots. www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31224-8/fulltext 2. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. https://doi.org/10.1371/journal.pntd.0007059 3. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. www.ajtmh.org/view/journals/tpmd/99/2/article-p404.xml 4. A Review and Database of Snake Venom Proteomes. https://pubmed.ncbi.nlm.nih.gov/28927001/ 5. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. https://pubmed.ncbi.nlm.nih.gov/27571102/ 6. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. www.ncbi.nlm.nih.gov/pmc/articles/PMC7076770/ 7. Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO). https://clinicaltrials.gov/ct2/show/NCT04996264

keywords:N/A

N/A

Total Funding

34

Number of Employees

$2.6M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.6M343%N/A
#2
$3.9M35N/AN/A
#3
$9.1M42-16%N/A
#4
$9.3M4319%N/A
#5
$12.9M49-4%N/A